Durata Therapeutics (FRA:DTA) Debt-to-Revenue : 1.61 (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is Durata Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Durata Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was €1.16 Mil. Durata Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was €49.28 Mil. Durata Therapeutics's annualized Revenue for the quarter that ended in Sep. 2014 was €31.29 Mil. Durata Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2014 was 1.61.

Durata Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Durata Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Durata Therapeutics Debt-to-Revenue Chart

Durata Therapeutics Annual Data

Trend

Dec11

Dec12

Dec13

Debt-to-Revenue

N/A

Durata Therapeutics Quarterly Data
	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Debt-to-Revenue	Get a 7-Day Free Trial							N/A	N/A	N/A	N/A	1.61

Competitive Comparison of Durata Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Durata Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Durata Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Durata Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Durata Therapeutics's Debt-to-Revenue falls into.

Durata Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Durata Therapeutics's Debt-to-Revenue for the fiscal year that ended in Dec. 2013 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(0	+	18.25)	/	N/A
	=	N/A

Durata Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2014 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(1.164	+	49.276)	/	31.292
	=	1.61

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2014) Revenue data.

Durata Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Durata Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Durata Therapeutics (FRA:DTA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Durata Therapeutics Inc (FRA:DTA) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.duratatherapeutics.com

Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.

Durata Therapeutics (FRA:DTA) Headlines

No Headlines